Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients | BMC Cancer | Full Text

Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients | BMC Cancer | Full Text

Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients

The treatment of choice for advanced non–small cell lung cancer is selected according to the presence of specific alterations. Patients should undergo molecular testing for relevant modifications and the mutat...

Authors:Luciene Schluckebier, Rosangela Caetano, Osvaldo Ulises Garay, Giuliana T. Montenegro, Marcelo Custodio, Veronica Aran and Carlos Gil Ferreira

Citation:BMC Cancer 2020 20:875

Content type:Research article

 

Published on: 14 September 2020

• ViewFull Text
 
• ViewPDF